In addition, an ongoing, multicentric phase II study (NCT04260126), called VERSATILE002, is evaluating the safety and efficacy of a combination of PDS0101 and pembrolizumab in checkpoint-naïve subjects with R/M/P HPV-16+ and PDL1+ HNSCC. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.